Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(7): e22090.
Published online 2011 July 20. doi:  10.1371/journal.pone.0022090
PMCID: PMC3140492

Genetic Cross-Interaction between APOE and PRNP in Sporadic Alzheimer's and Creutzfeldt-Jakob Diseases

Andrew Francis Hill, Editor


Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD) represent two distinct clinical entities belonging to a wider group, generically named as conformational disorders that share common pathophysiologic mechanisms. It is well-established that the APOE ε4 allele and homozygosity at polymorphic codon 129 in the PRNP gene are the major genetic risk factors for AD and human prion diseases, respectively. However, the roles of PRNP in AD, and APOE in CJD are controversial. In this work, we investigated for the first time, APOE and PRNP genotypes simultaneously in 474 AD and 175 sporadic CJD (sCJD) patients compared to a common control population of 335 subjects. Differences in genotype distribution between patients and control subjects were studied by logistic regression analysis using age and gender as covariates. The effect size of risk association and synergy factors were calculated using the logistic odds ratio estimates. Our data confirmed that the presence of APOE ε4 allele is associated with a higher risk of developing AD, while homozygosity at PRNP gene constitutes a risk for sCJD. Opposite, we found no association for PRNP with AD, nor for APOE with sCJD. Interestingly, when AD and sCJD patients were stratified according to their respective main risk genes (APOE for AD, and PRNP for sCJD), we found statistically significant associations for the other gene in those strata at higher previous risk. Synergy factor analysis showed a synergistic age-dependent interaction between APOE and PRNP in both AD (SF = 3.59, p = 0.027), and sCJD (SF = 7.26, p = 0.005). We propose that this statistical epistasis can partially explain divergent data from different association studies. Moreover, these results suggest that the genetic interaction between APOE and PRNP may have a biological correlate that is indicative of shared neurodegenerative pathways involved in AD and sCJD.


Both Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD) are brain amyloidoses associated with old age. Although, they represent two distinct clinical entities, AD and CJD are now considered as part of a wider group generically named as conformational disorders, and more specifically brain amyloidosis. These two disorders share common pathophysiologic mechanisms involving protein deposits in the brain due to the conversion of a soluble, normal protein into an insoluble, aggregated form leading to fatal degeneration [1][5]. From an etiological standpoint, both AD and CJD can be classified as sporadic and familial forms (and also as acquired in CJD). The sporadic cases (sporadic CJD –sCJD- and late onset AD) represent the most frequent forms; and although of unknown aetiology, several genetic risk factors have been described. The APOE ε4 allele is a major risk factor for AD [6], [7]; whereas homozygosity at polymorphic codon 129 (Met to Val) in the PRNP gene is a well-established susceptibility marker for human prion diseases [8]. However, the role of APOE in CJD and PRNP in AD is matter of discussion.

Previous studies on the distribution of PRNP codon 129 in AD, or the APOE ε4 allele in CJD yielded conflicting results. Some studies found an association between the PRNP codon 129 and AD [9][11], while others did not [12][19]. Likewise, some studies found an association between the presence of the APOE ε4 allele and CJD [20], [21], while others reports were negative [22][27].

Since these disorders share several features, a genetic interaction between these genes might determine susceptibility to both diseases or modulate the clinical phenotypes. A potential genetic interaction between APOE and PRNP genes has been rarely studied for CJD or AD. Furthermore, to our knowledge, an analysis of the potential epistasis of these genes in both disorders by using the same control population and statistical approach has never been materialized. In this study, we investigated a possible genetic interaction between APOE ε4 allele and the polymorphic codon 129 of the PRNP gene in both AD and sCJD populations.


In this study, two different patient (AD and sCJD) and one control populations were analyzed. The control group consisted of 335 subjects; 198 (59.1%) women and 137 (40.9%) men. Age at study inclusion for control individual followed a non-normal distribution with a mean of 73.2 years and standard deviation of 11.0 years. The AD group consisted of 474 patients diagnosed with probable AD according to the NINCDS-ADRDA criteria; 323 were women (68.1%) and 151 were men (31.9%). Age at onset for control individuals followed a non-normal distribution with a mean of 74.5±8.2 years. The sCJD group (n = 175) included 140 (80.0%) definite, neuropathologically verified patients, and 35 (20.0%) probable cases that were diagnosed with sCJD. The gender distribution was 87 (49.7%) women and 88 (50.3%) men. Age at onset for this group followed a non-normal distribution with a mean of 67.3±11 years. No statistically significant differences in gender distribution or age at onset were found between definite and probable sCJD cases.

Analysis of gender distribution showed statistically significant differences between AD (p = 0.010) or sCJD (p = 0.049) patients and the control group. Analysis of age distribution yielded statistically significant differences for sCJD patients (p<0.001), and for AD patients (p = 0.006) compared to the control group. Mean age and gender distribution of the control population were intermediate between those of AD and sCJD cases, supporting its validity as a common control group. In order to correct for potential effects of the differential gender and age distributions, odds ratios and synergy factors were obtained from logistic regression algorithms controlling by age and gender.

The distribution of the polymorphic codon 129 of PRNP and APOE genotypes in control subjects, AD and sCJD patients are shown in Table 1. APOE polymorphic variants at codon 112 and codon 158, as well as the allelic haplotypes ε2/ε3/ε4, were in Hardy-Weinberg equilibrium in the three populations studied. As expected, the polymorphic codon 129 of the PRNP gene was in Hardy-Weinberg equilibrium in the healthy control and AD populations, but in clear disequilibrium (p<0.0001) in the sCJD population.

Table 1
APOE and PRNP codon 129 genotypic and allelic frequencies in control subjects (Cont) and patients (AD, sCJD).


As shown in Table 2, and previously repeatedly described in the literature, we found an increased risk of AD in APOE ε4 allele carriers (OR = 4.51). Interestingly, when this association was studied in different strata according to PRNP codon 129 genotypes, we observed an increase in the OR associated with the presence of M129 alleles. Thus, the highest OR (7.28) was observed in M129M homozygous, while the lowest OR in V129V homozygous (2.06). The Mantel-Haenszel test for homogeneity indicated that these two homozygous strata were statistically significant different (p = 0.026). The fact that the OR for each stratum is different and the global OR appears to be an average OR suggested an interaction between APOE and PRNP, rather than PRNP acting as a confounding factor.

Table 2
Odds ratios for the association between Alzheimer's disease and APOE ε4 carriers (vs. APOE ε4 non-carriers) among different strata defined by PRNP codon 129 genotypes.

Additionally, we also observed a decreased risk of AD in APOE ε2 allele carriers (OR = 0.50, 95% CI: 0.30–0.82, p = 0.006). Similar to the results with the APOE ε4 allele carriers, when this analysis was performed in the 3 different strata defined by PRNP codon 129, we found a tendency to higher protection associated with the presence of PRNP V129 alleles (M129M: OR = 0.61, 95% CI: 0.28–1.31, p = 0.20; and M129V: OR = 0.55, 95% CI: 0.25–1.21, p = 0.14; and V129V: OR = 0.25, 95% CI: 0.07–0.91, p = 0.036).

The analysis of AD risk related to the status of PRNP codon 129 (Table 3) indicated a non-significant association trend for the M129 allele (OR = 1.23, p = 0.057), as well as for the M129M (OR = 1.47) and M129V (OR = 1.16) genotypes compared to homozygous V129V for the whole AD population. However, after stratification of AD subjects according to their APOE ε4 status, we found a clear association (OR = 3.94, p = 0.007) for M129M homozygous only in APOE ε4 carriers. In this APOE ε4+ stratum, the analysis of dose effect indicated a two-fold increase in AD risk (OR = 2.02, p = 0.004) for each PRNP M129 allele carried. A similar analysis for APOE ε2 carriers did not show any significant association in any strata.

Table 3
Odds ratios for the association between Alzheimer's disease and PRNP codon 129 in different strata defined by APOE ε4 allele status (V129V genotype and V129 allele are taken as reference or non-exposed).

Altogether, these findings suggested that the M129 allele of the PRNP gene is a susceptibility genetic risk factor of AD only in APOE ε4 carriers and prompted us to further explore the potential genetic interaction between APOE and PRNP in the AD population. In order to study the combined gene effects, we analyzed the risk of developing AD for subjects carrying both traits (APOE ε4 carriers and PRNP M129M homozygous) compared to subjects without these traits (Table 4). M129M homozygous subjects carrying at least one APOE ε4 allele have a 7.68-fold (p<0.0001) increased risk of developing AD compared to subjects V129V with no APOE ε4 alleles, which is higher than the expected combined effect of the individual contributions of APOE ε4 and PRNP M129M, suggesting gene-gene interaction or epistasis (Table 4, upper).

Table 4
Synergy in AD population between APOE and PRNP genes.

In order to measure the size and significance of the interaction, we performed a synergy factor (SF) analysis following reported methods. According to this analysis, we obtained a SF of 3.59, which is statistically significant different (p = 0.027) from 1; indicating a synergistic interaction between two risk factors, APOE ε4 and M129M (Table 4, upper). A similar analysis by PRNP alleles (M129 vs. V129) indicated a SF of 1.86 (p = 0.018) for the interaction APOE ε4 and a M129 allele (Table 4, bottom).


As shown in Table 5, an increased risk for sCJD was associated with M129M (OR = 4.61) and V129V (OR = 3.20) homozygous compared to M129V heterozygous at codon 129 of the PRNP gene. Interestingly, when these associations were studied in different strata according to the APOE ε4 status, we observed an important increase in the OR for APOE ε4 carriers compared to non-ε4 carriers (28.5 vs. 3.5 for M129M and 13.2 vs. 2.43 for V129V). Mantel-Haenszel tests for homogeneity indicated that the APOE ε4 carriers were statistically significant different from APOE ε4 non-carriers for the M129M comparison (p = 0.022). These data, as in the case of the AD population, suggested an interaction between APOE and PRNP in sCJD. The analysis of the APOE ε4 allele dose effect (no, one or two copies of APOE ε4 allele) showed similar results, although of lower magnitude to the ones observed for the ε4+ and no-ε4 allele comparison (M129M OR = 2.26 p = 0.023; M129V OR = 0.68 p = 0.48; V129V OR = 1.26 p = 0.68; Homozygosity OR = 1.89 p = 0.032), suggesting that the effect of APOE ε4 allele was dose dependent.

Table 5
Odds ratios for the association between CJD and PRNP codon 129 in different strata defined by APOE ε4 allele status (M129V genotype is taken as reference or non-exposed).

We found no association between APOE ε4 allele status and sCJD for the total population (OR = 1.46, p = 0.13) (Table 6). However, when the different genotypes of PRNP codon 129 were analyzed individually, a statistical significant risk associated with the APOE ε4 allele was observed in the M129M homozygous stratum (OR = 2.47, p = 0.017). We also found a similar trend, although not statistically significant, in the V129V homozygous stratum. Opposite, a non significant protector effect for the APOE ε4 allele was found in M129V heterozygous stratum. Mantel-Haenszel test indicated significant differences between the M129M homozygous and M129V heterozygous strata (p = 0.022) or homozygous (M129M and V129V) vs. M129V heterozygous (p = 0.027). We did not find association for the APOE ε2, neither in the unselected domain (all sCJD/control populations), nor in any of the subpopulations defined by PRNP codon 129 genotypes.

Table 6
Odds ratios for the association between CJD and APOE ε4 carriers (vs. APOE ε4 non-carriers) among different strata defined by PRNP codon 129 genotypes.

In order to study the combined gene effects between APOE and PRNP in sCJD, we analyzed the risk of developing sCJD for subjects carrying both traits (APOE ε4 carriers and PRNP homozygous) compared to subjects without these traits (Table 7 top). PRNP homozygous subjects carrying at least one APOE ε4 allele have a 6.83-fold (p<0.0001) increased risk of developing sCJD than subjects M129V heterozygous with no APOE ε4 alleles. This increased risk appears to be higher than a multiplicative effect of each independent factor, suggesting gene-gene interaction or epistasis. Synergy factor analysis yielded a SF of 7.26, which is statistically significant different (p = 0.005) from 1; indicating a synergistic interaction between two risk factors, APOE ε4 and PRNP homozygous. A similar analysis by PRNP genotypes (M129M vs. M129V) indicated a SF of 8.48 (p = 0.003) for the interaction APOE ε4 and PRNP M129M genotype (Table 7, bottom).

Table 7
Synergy in sCJD population between APOE and PRNP genes.

APOE and PRNP influence on disease onset and duration

We further explored the influence of these genetic factors on disease onset for both AD and sCJD populations. In AD, we observed that APOE ε4 carriers had an earlier onset than non-ε4 carriers (72.8±7.0 years vs. 75.7±8.8 years, p<0.001), in agreement with previous reports [6], [28]. We also observed a non-significant trend for later onset of APOE ε2 carriers compared to non-ε2 carriers (76.8±10.8 years vs. 74.3±8.0 years, p<0.50), as previously reported [29]. On the other hand, we did not find any association with onset for the 3 different genotypes related to the codon 129 of PRNP (M129M: 74.1±8.1 years, M129V: 74.7±8.0 years, V129V: 75.5±9.5 years, p = 0.62).

For sCJD, we found a non-significant tendency for earlier onset associated with the PRNP V129 allele (M129M: 68.4±10.6 years, M129V 66.6±11.3 years, V129V: 63.0±11.6 years, p = 0.13). Regarding APOE, we observed a later onset for APOE ε2 carriers compared to non-ε2 carriers (72.2±7.8 years vs. 66.7±11.2 years, p = 0.046) in agreement to previous reports [30]; while we failed to detect any effect for the APOE ε4 allele (67.8±10.5 years vs. 67.2±11.2 years, p = 0.75), also in agreement with previous results [27].

Additionally, we also explored the influence of these genetic factors on disease duration in sCJD population. We observed a significant longer disease duration in PRNP M129V heterozygous compared to PRNP homozygous (p<0.001) (M129M: 5.3±4.5 months, M129V: 13.1±7.7 months, V129V: 4.9±1.4 months). These results are in concordance with previous reports about the classification sCJD in several subtypes characterized by a combination of PRNP codon 129 status and the size of protease resistant PrPSc fragments and disease phenotype [31], [32]. On the other hand, we did not find any association with disease duration for either APOE ε2 allele or APOE ε4 allele carriers.

We also study whether the synergistic effects observed between APOE ε4 and PRNP M129 was age dependent. For this purpose, we stratified cases and controls into two groups according to the median age for patients and control population pooled together. Analysis of AD risk related to the status of PRNP of the age stratified data indicated that the association to the PRNP M129 allele previously found in the APOE ε4 carriers stratum (see Table 3) was mainly determined by individuals with earlier onset (onset before 74 years old: OR = 2.33, 95% CI: 1.23–4.42, p = 0.009; onset at or after 74 years old: OR = 1.47, 95% CI: 0.66–3.25, p = 0.35) (see Figure 1, right).

Figure 1
Synergistic age-dependent interaction between APOE and PRNP in both AD and sCJD.

Similarly, analysis of sCJD risk related to the APOE ε4 status of the age stratified data showed that the association for APOE ε4 previously found in the PRNP homozygous strata (see Table 6) was mainly driven by individuals with later onset (onset before 71 years old: OR = 1.64, 95% CI: 0.72–3.74, p = 0.24; onset at or after 71 years old: OR = 3.27, 95% CI: 1.27–8.43, p = 0.014) (see Figure 1, left).


A considerable number of studies have addressed association analysis of PRNP codon 129, a well-established genetic risk factor for sCJD, with AD; as well as the association of APOE ε4 allele, the major genetic risk factor for late onset AD, with sCJD. While the potential interaction between APOE and PRNP has been studied in AD populations, yielding controversial results [9], [11], [14], [16], [33], [34], few reports on the potential interaction between APOE and PRNP in sCJD have been published [24], [27]. The idea of undertaking a combined genetic analysis of sporadic AD and sCJD searching for interactions was motivated by reports on: i) the potential role of PrP in AD [35][41], and ii) because as brain amyloidoses, AD and sCJD, share several epidemiologic features such as an age at onset concordant with the clinical course duration, and vascular risk factors well established for AD and recently suggested for sCJD [3], [42], [43].

A part of our results mainly correspond to confirmatory data. Subjects bearing at least one APOE ε4 allele have 4.51-fold increased risk of developing AD in comparison with those that do not carry this allele (Table 2). Homozygosity at PRNP codon 129 increases risk of sCJD: 4.61-fold for M129M and 3.2-fold for V129V compared to M129V heterozygous (Table 5). Analysis of the risk attributable to PRNP in the overall AD population showed a statistically non-significant association (Table 2), of similar size and direction than the meta-analysis based on periodically updated data published at [44]. A similar analysis for the association of APOE in the overall sCJD population showed no association for the APOE ε4 allele (Table 5), nor for the APOE ε2 allele.

Hidden effects in overall analyses were unveiled by stratification according to their respective main risk genes (APOE ε4 allele status for AD, and PRNP genotypes for sCJD). We found statistically significant associations for the other gene in those strata at higher previous risk (APOE ε4 carriers for AD, and PRNP M129M homozygous for sCJD), suggesting an underlying interaction between APOE and PRNP as risk factors for both disorders (see Tables 3 and and6).6). The synergy factor analysis in AD and sCJD confirmed the interaction between these two genes as risk factors in both AD (SF = 3.59, p = 0.027), and sCJD (SF = 7.26, p = 0.005) (see Tables 4 and and7).7). Thus, subjects who carried a PRNP M129M genotype and at least one APOE ε4 allele for AD, or PRNP homozygous subjects that carried at least one APOE ε4 allele for sCJD have an increased risk that represent a deviation from a multiplicative model for the combined effects of these genetic factors.

It is understandable that a genetic interaction or epistasis given by statistical significant SF values does not necessarily correlate with a biological epistasis [45]. Provided there is a biological interaction, PRNP codon 129 appears to act a risk factor, at least in part, by different molecular mechanisms in AD and sCJD. While the risk of AD is associated with the PRNP M129 allele among APOE ε4 carriers, the increased risk of sCJD is associated with PRNP codon 129 homozygous (both M129M and V129V). Interestingly, we found that these interactions between PRNP and APOE were also age-dependent for both disorders, but in opposite directions (see Figure 1). While the increased risk of the PRNP M129 allele on APOE ε4 carriers was mainly associated with individuals with earlier AD onset; the APOE ε4 allele risk on PRNP codon 129 homozygous was mainly patent in the population with later sCJD onset. These results suggest that APOE and PRNP act as risk factors with different age-related timings, perhaps in correlation with differences in age-specific incidences for AD and sCJD. Thus, PRNP appears to be a genetic risk factor with an influence early during aging both in AD and sCJD, while APOE ε4 has a later expression. Several interrelated questions rise about the roles of APOE and PRNP interaction. First, if they determine the shape of the age-specific incidence curves shifting peaks in different directions; second, if they are related to disease course duration; third, if they are related to the vascular pathway and determine susceptibility pointing to same or different gene-environment interactions. Similarly, a recent report on rapidly progressive Alzheimer's disease has found that both APOE and PRNP may modulate the phenotypic expression of the disease [46].

Central to both neurodegenerative pathologies is an analogous proteolytic processing of a membrane protein (APP in AD, and cellular PrP in prion disorders) that generates unstable, aggregation prone, neurotoxic fragments that are pathognomonic for each disease (Aβ peptides and PrPSc). The coexistence of AD and CJD pathology in a subgroup of sCJD patients [47], the colocalization of PrPSc and Aβ peptides in amyloid lesions both in sCJD and AD [48][52], and a synergist effect between AD and prion pathologies [53] have suggested common pathways involved in the generation or clearance of Aβ peptides and PrPSc [47]. In this sense, some appealing findings are starting to delineate shared regulatory mechanism that involves the amyloid beta peptides and their precursor protein (APP) and cellular PrP.

On one side, PrP regulates the levels of Aβ peptides by decreasing the cleavage of APP by BACE1 [35], [36]. On the other side, cellular PrP protein has been also identified as a high-affinity receptor for Aβ oligomers, the pathological species responsible for Alzheimer's disease, mediating their deleterious effects [37][41]. In order to reconcile the diverse roles of cellular PrP in Aβ metabolism, it has been proposed a feedback loop where, in normal brain, the levels of Aβ peptides regulates cellular PrP expression that in turn exerts an inhibitory effect on BACE1, decreasing Aβ levels. In AD, this feedback loop is disrupted by ever-increasing levels of Aβ oligomers that bind to cellular PrP shifting its interaction with BACE1, and therefore, preventing its regulation [35], [54].

Cerf and collaborators [55] observed that apoE4 strongly stabilizes Aβ oligomers, besides its reduced ability to clear these toxic forms of Aβ [56][59]. At genetic level, Combarros and collaborators [45] in a recent review about potential interactions between genes pairs in AD, reported that so far the only consistently replicated interaction was that between BACE1 exon5 GG and APOE4. In this paper, we are reporting the interaction between PRNP M129M and APOE4 in AD. Having in mind these facts, and based on the feed-back regulation discussed, we propose a potential mechanism for biological epistasis between the APOE ε4 allele and the PRNP M129 allele in AD. According to this model, we suggest that apoE4 preferential binding and stabilization of Aβ oligomers favour Aβ delivery to cellular PrP, instead of its targeting for cellular clearance; therefore disrupting the regulatory feed-back. Moreover, apoE has been shown to promote Dab1 phosphorylation that in turns regulates APP processing [60]. ApoE4 compared to apoE3 results in lower levels of phophorylated Dab1 and increased levels of Aβ peptides [58], [60]. In AD pathogenesis, Aβ oligomers may further sequester apoE, precluding regulation of APP processing mediated by Dab1, and promoting processing by BACE1 as above discussed.

The question whether the PRNP polymorphism affect the interaction of Aβ oligomers with cellular PrP was already posed by Kim and Tsai [61]. Interestingly, Parkin and collaborators [35] found an increase in Aβ40 peptide levels in brains of M129M mice compared to V129V, suggesting that cellular PrP M129 is less efficient inhibiting BACE1 activity. We propose that cellular PrP V129 could have a protective role in AD through a stronger inhibitory effect on BACE1 activity and weaker affinity for Aβ oligomers as a consequence of its particular structure.

As previously discussed, homozygosity at PRNP codon 129 is the main genetic driving force in sCJD disease [62] that correlates with a increased tendency to form toxic self-propagating PrPSc oligomers [63], [64]. A model where apoE4 stabilizes PrP oligomers, and impairs their clearance may also explain the synergistic association between PRNP and APOE in sCJD. Moreover, similar to apoE, PrPSc has been shown to affect to Dab1 phosphorylation and Aβ production [65], [66]. These data appear to explain the inverse correlation between PrPSc deposits and Abeta plaques in sCJD and animal models [35], [66]; and suggest new routes of convergence for AD and prion pathologies. Future studies are needed to elucidate the role of apoE4 in relation with cellular PrP and PrPSc oligomers for the development of the disease. However, analogously to AD, other effects of apoE-independent from PrP metabolism, such as cholesterol transport and synaptic plasticity and repair, and vascular implications may prove to be relevant for sCJD [67][70], [43].

In our opinion, this study has several features of relevance. We have investigated for the first time, APOE and PRNP genotypes simultaneously in the sporadic forms of AD and CJD compared to the same control population, with an age distribution intermediate between sCJD and AD cases. Potential bias by population stratification was minimized by selection of ethnically matched cases and controls from limited sources. Finally, the analysis of sCJD includes an important number of patients with definite diagnosis by anatomopathological study.

Unfortunately, the study has also limitations. Most important, the AD cases are selected solely on a clinical diagnosis basis; no anatomopathologically confirmed AD cases were included. Moreover, since our AD cases are not completely characterised by genetic analysis, some cases may correspond to genetic cases. However, given the low frequency of familial cases, and that all our AD cases are over 55 years with no aggregation of early onset cases in their family, it is unlikely that this fact may alter the results here discussed. Also, although the study populations are relative large, there are a small number of cases in some less frequent strata that may pose an increased risk of false positive results. Finally, only a limited sample of a Spanish population is included in the analysis, and therefore, perhaps the results are not suitable for other populations.

Discrepancies among results, including ours, can be related to ethnic differences or to the presence of additional factors influencing risk that are not included in the analyses [71][73]. Some authors have suggested that the lack of replication among different studies could be also related to epistasis or gene-gene interaction [45], [74], [75]. Of special relevance for this work, it is the study by Combarros and collaborators [12]; where opposite to our results, they did not find any association for the PRNP gene with the risk of developing AD, even after stratifying by APOE ε4 allele status in a Spanish population. Taking into account that even in our study the association effect is small; this discrepancy may be explained by the different geographic distribution of the studied populations that may play an important role in the interpretation of the results [16], [45], [76]. Thus, although both populations are of Spanish origin, Combarros' population is restricted to North of Spain, while ours have been recruited mainly from two different Spanish geographical areas (Eastern and Central areas). Perhaps most relevant, having in mind that we have found an age-dependent epistasis, the discrepancy between the two studies can be related to the different age distributions for the AD patients and controls included in these studies.

In summary, our data confirmed APOE ε4 and homozygosity at PRNP as major genetic risks for developing AD and sCJD, respectively. More interestingly, we found statistically significant age-dependent epistasis between these genes for both AD and sCJD, suggesting common pathways involved in the generation, clearance and neurotoxic signal transduction of Aβ peptides and PrP in AD and sCJD. Additional studies exploring larger populations are required to confirm our findings.

Materials and Methods

Patients and controls

Study population was composed of 474 AD patients diagnosed as “probable AD” according to NINCDS-ADRDA criteria [77] (patients with family history of dementia were not included), 175 sCJD patients and 335 control subjects with normal cognitive status. All subjects were Caucasians of Spanish origin (Eastern and Central areas). The study was approved by the Bioethics and Animal Welfare Committee (Comité de Bioética y Bienestar Animal) from the Instituto de Salud Carlos III, Madrid, Spain; and by the Ethical Research Committees (Comités de Ética en la Investigación) from the CIEN Foundation, and Universidad Autónoma de Madrid, Madrid, Spain. All samples for sCJD cases analyzed in this study were obtained from patients with suspected prion diseases, submitted for diagnostic purposes under the guidelines of the Spanish National Referral and Surveillance system. AD and control samples were obtained with the adequate understanding and written consent of subjects, family members or legal guardians, as appropriate. For this study, all samples were coded and personal information dissociated from the test results, according to local legislation at the time of analysis. All the data were analyzed anonymously, and all clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki.

DNA analysis

Total DNA was isolated from peripheral blood or cerebral tissue following standard procedures. Genotyping of APOE polymorphisms (rs429358 and rs7412) was determined by Real-Time PCR [78] or with FRET probes [79] and the analysis of the polymorphism at codon 129 of the PRNP gene (rs1799990) was performed by DNA sequencing using specific primers [80].

Statistical methods

Statistical analyses of nominal or categorical variables were performed by Fisher's exact text or Pearson's chi-square test. Quantitative variables (age at onset, disease duration) were analyzed by non-parametric statistical hypothesis contrast with Mann-Whitney U test. Additionally, logistic regression models controlled by age (as a linear variable) and gender were used to compare genotypic and allelic frequencies and to calculate association adjusted odds ratio (OR) and 95% confidence intervals (CIs). The Hardy-Weinberg test for genotype frequency distributions was performed on the observed genotype frequencies for population, with significance based on a standard observed-expected 2 with 1 df. The Mantel-Haenszel test was used to estimate the common odds ratio and to test whether the overall degree of association across different genotype strata was significant. Deviations from normality of quantitative variables were checked by the Kolmogorov-Smirnov statistic with Lilliefors' significance. The synergy factor (SF), confidence intervals and significance were calculated as previously described [45], [81]. All statistical analyses were performed with the GraphPad 4 or PASWStatistics 18 softwares.


We thank the CIEN Foundation and Drs. P. Gil and P. Coria for the recruitment of the Alzheimer's cases, and to I. Sastre for her excellent technical work in the management of the DNA bank. We also thank the epidemiological and clinical coordinators for assistance and notifying cases to the CJD Spanish Registry, as well as to F. Avellanal, J. Almazán, M. Ruiz, and E. Alcalde for their collaboration with the Spanish CJD surveillance system. We are grateful to the Asociación para las Familias con Alzheimer (AFALcontigo) from Madrid for their help. This work was made possible by the generous participation of patients, control subjects and their families.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grants FIS 05/0912 from the Ministerio de Ciencia e Innovación, DGSP from Ministerio de Sanidad, Política Social e Igualdad (MC), and the Spanish CIBERNED network (AL, FV, JdP, IF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Gambetti P, Russo C. Human brain amyloidoses. Nephrol Dial Transplant. 1998;13(Suppl 7):33–40. [PubMed]
2. Checler F, Vincent B. Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators. Trends Neurosci. 2002;25(12):616–620. [PubMed]
3. Aguzzi A, Haass C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science. 2003;302(5646):814–818. [PubMed]
4. Armstrong RA, Lantos PL, Cairns NJ. Overlap between neurodegenerative disorders. Neuropathology. 2005;25(2):111–124. [PubMed]
5. Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci. 2006;31(8):465–472. [PubMed]
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921–923. [PubMed]
7. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43(8):1467–1472. [PubMed]
8. Mead S. Prion disease genetics. Eur J Hum Genet. 2006;14(3):273–281. [PubMed]
9. Golanska E, Hulas-Bigoszewska K, Rutkiewicz E, Styczynska M, Peplonska B, et al. Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD. Neurology. 2004;62(2):313–315. [PubMed]
10. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology. 2004;63(2):364–366. [PubMed]
11. Gacia M, Safranow K, Styczyńska M, Jakubowska K, Pepłońska B, et al. Prion protein gene M129 allele is a risk factor for Alzheimer's disease. J Neural Transm. 2006;113(11):1747–1751. [PubMed]
12. Combarros O, Sánchez-Guerra M, Llorca J, Alvarez-Arcaya A, Berciano J, et al. Polymorphism at codon 129 of the prion protein gene is not associated with sporadic AD. Neurology. 2000;55(4):593–595. [PubMed]
13. Casadei VM, Ferri C, Calabrese E, Grimaldi LM, Franceschi M, et al. Prion protein gene polymorphism and Alzheimer's disease: one modulatory trait of cognitive decline? J Neurol Neurosurg Psychiatry. 2001;71(2):279–280. [PMC free article] [PubMed]
14. Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol. 2003;53(3):409–412. [PubMed]
15. Li X, Rowland LP, Mitsumoto H, Przedborski S, Bird TD, et al. Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol. 2005;58(6):858–864. [PubMed]
16. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, et al. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging. 2006;27(5):770.e1–770.e5. [PubMed]
17. Poleggi A, Bizzarro A, Acciarri A, Antuono P, Bagnoli S, et al. Codon 129 polymorphism of prion protein gene in sporadic Alzheimer's disease. Eur J Neurol. 2008;15(2):173–178. [PubMed]
18. Cousin E, Macé S, Rocher C, Dib C, Muzard G, et al. No replication of genetic association between candidate polymorphisms and Alzheimer's disease. Neurobiol Aging. 2009 2009 Nov 2. [Epub ahead of print] [PubMed]
19. Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, et al. Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics. 2009;10(1):19–25. [PMC free article] [PubMed]
20. Amouyel P, Vidal O, Launay JM, Laplanche JL. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet. 1994;344(8933):1315–1318. [PubMed]
21. Van Everbroeck B, Croes EA, Pals P, Dermaut B, Jansen G, et al. Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt-Jakob Disease phenotype. Neurosci Lett. 2001;313(1–2):69–72. [PubMed]
22. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993;342(8873):710–711. [PubMed]
23. Zerr I, Helmhold M, Armstrong VW, Weber T. Apolipoprotein E in Creutzfeldt-Jakob disease. Lancet. 1995;345(8941):68–69. [PubMed]
24. Salvatore M, Seeber AC, Nacmias B, Petraroli R, D'Alessandro M, et al. Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Neurosci Lett. 1995;199(2):95–98. [PubMed]
25. Friedman G, Gabizon R, Ben-Yehuda A. Apolipoprotein Eepsilon4 allele, a risk factor for late onset nonfamilial Alzheimer's disease among Israeli Jews. Arch Gerontol Geriatr. 1997;24(2):175–181. [PubMed]
26. Zerr I, Helmhold M, Poser S, Armstrong VW, Weber T. Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Arch Neurol. 1996;53(12):1233–1238. [PubMed]
27. Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, et al. Amyloid-β 1–42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease. J Alzheimers Dis. 2011;23(4):717–726. [PubMed]
28. Chapman J, Korczyn AD, Karussis DM, Michaelson DM. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology. 2001;57(8):1482–1485. [PubMed]
29. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180–184. [PubMed]
30. Pickering-Brown SM, Mann DM, Owen F, Ironside JW, de Silva R. Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neurosci Lett. 1995;187(2):127–129. [PubMed]
31. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull. 2003;66:213–239. [PubMed]
32. Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain. 2003;126(Pt 6):1333–1346. [PubMed]
33. Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, et al. Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology. 1998;51(3):734–737. [PubMed]
34. Giannattasio C, Poleggi A, Puopolo M, Pocchiari M, Antuono P, et al. Survival in Alzheimer's disease is shorter in women carrying heterozygosity at codon 129 of the PRNP gene and no APOE epsilon 4 allele. Dement Geriatr Cogn Disord. 2008;25(4):354–358. [PubMed]
35. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A. 2007;104(26):11062–11067. [PubMed]
36. Kellett KA, Hooper NM. Prion protein and Alzheimer disease. Prion. 2009;3(4):190–194. [PMC free article] [PubMed]
37. Nygaard HB, Strittmatter SM. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. Arch Neurol. 2009;66(11):1325–1328. [PMC free article] [PubMed]
38. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457(7233):1128–1132. [PMC free article] [PubMed]
39. Gunther EC, Strittmatter SM. Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med. 2010;88(4):331–338. [PMC free article] [PubMed]
40. Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, et al. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci. 2010;11:130. [PMC free article] [PubMed]
41. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;5;30(18):6367–6374. [PMC free article] [PubMed]
42. Price DL, Borchelt DR, Sisodia SS. Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses. Proc Natl Acad Sci U S A. 1993;90(14):6381–6384. [PubMed]
43. de Pedro-Cuesta J, Mahillo-Fernandez I, Rabano A, Calero M, Cruz M, et al. Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results from a risk-based assessment of surgical interventions. J Neurol Neurosurg Psychiatry. 2011;82(2):204–212. [PMC free article] [PubMed]
44. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17–23. [PubMed]
45. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ. Epistasis in sporadic Alzheimer's disease. Neurobiol Aging. 2009;30(9):1333–1349. [PubMed]
46. Schmidt C, Redyk K, Meissner B, Krack L, von Ahsen N, et al. Clinical features of rapidly progressive Alzheimer's disease. Dement Geriatr Cogn Disord. 2010;29(4):371–378. [PubMed]
47. Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, et al. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis. 2008;5(6):347–354. [PubMed]
48. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, et al. Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 1998;96(2):116–122. [PubMed]
49. Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, et al. Prion protein expression in senile plaques in Alzheimer's disease. Acta Neuropathol. 2001;101(1):49–56. [PubMed]
50. Voigtländer T, Klöppel S, Birner P, Jarius C, Flicker H, et al. Marked increase of neuronal prion protein immunoreactivity in Alzheimer's disease and human prion diseases. Acta Neuropathol. 2001;101(5):417–423. [PubMed]
51. Kovacs GG, Zerbi P, Voigtländer T, Strohschneider M, Trabattoni G, et al. The prion protein in human neurodegenerative disorders. Neurosci Lett. 2002;329(3):269–272. [PubMed]
52. Takahashi RH, Tobiume M, Sato Y, Sata T, Gouras GK, et al. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain. Neuropathology. 2010;2010 Nov 9 [Epub ahead of print] [PubMed]
53. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, et al. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci. 2010;30(13):4528–4535. [PMC free article] [PubMed]
54. Rushworth JV, Hooper NM. Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis. 2010;2010 Dec 27 [PMC free article] [PubMed]
55. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert J.-M, Raussens V. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J. 2011 2011 Jan 25. [Epub ahead of print] [PubMed]
56. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63(3):287–303. [PMC free article] [PubMed]
57. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333–44. [PMC free article] [PubMed]
58. Sharman MJ, Morici M, Hone E, Berger T, Taddei K, et al. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis. 2010;21(2):403–409. [PMC free article] [PubMed]
59. Petrlova J, Hong HS, Bricarello DA, Harishchandra G, Lorigan GA, et al. A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution. Proteins. 2011;79(2):402–416. [PMC free article] [PubMed]
60. Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem. 2005;93(1):145–55. [PubMed]
61. Kim D, Tsai LH. Bridging physiology and pathology in AD. Cell. 2009;137(6):997–1000. [PubMed]
62. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352(6333):340–342. [PubMed]
63. Chiesa R, Piccardo P, Biasini E, Ghetti B, Harris DA. Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. J Neurosci. 2008;28(49):13258–13267. [PMC free article] [PubMed]
64. Minaki H, Sasaki K, Honda H, Iwaki T. Prion protein oligomers in Creutzfeldt-Jakob disease detected by gel-filtration centrifuge columns. Neuropathology. 2009;29(5):536–542. [PubMed]
65. Gavín R, Ureña J, Rangel A, Pastrana MA, Requena JR, et al. Fibrillar prion peptide PrP(106–126) treatment induces Dab1 phosphorylation and impairs APP processing and Abeta production in cortical neurons. Neurobiol Dis. 2008;30(2):243–254. [PubMed]
66. Gavín R, Ferrer I, del Río JA. Involvement of Dab1 in APP processing and beta-amyloid deposition in sporadic Creutzfeldt-Jakob patients. Neurobiol Dis. 2010;37(2):324–329. [PubMed]
67. Kesäniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest. 1987;80(2):578–581. [PMC free article] [PubMed]
68. Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol. 1999;10(3):207–217. [PubMed]
69. Gilch S, Kehler C, Schätzl HM. The prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci. 2006;31(2):346–353. [PubMed]
70. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med. 2010;16(6):287–294. [PubMed]
71. Mead S, Stumpf MP, Whitfield J, Beck JA, Poulter M, et al. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science. 2003;300(5619):640–643. [PubMed]
72. Eisenberg DT, Kuzawa CW, Hayes MG. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol. 2010;143(1):100–111. [PubMed]
73. Soldevila M, Andrés AM, Ramírez-Soriano A, Marquès-Bonet T, Calafell F, et al. The prion protein gene in humans revisited: lessons from a worldwide resequencing study. Genome Res. 2006;16(2):231–239. [PubMed]
74. Wade MJ. Epistasis, complex traits, and mapping genes. Genetica. 2001;112–113:59–69. [PubMed]
75. Moore JH, Williams SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. Bioessays. 2005;27(6):637–646. [PubMed]
76. Golanska E, Hulas-Bigoszewska K, Sieruta M, Zawlik I, Witusik M, et al. Earlier onset of Alzheimer's disease: risk polymorphisms within PRNP, PRND, CYP46, and APOE genes. J Alzheimers Dis. 2009;17(2):359–368. [PubMed]
77. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944. [PubMed]
78. Calero O, Hortigüela R, Bullido MJ, Calero M. Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan and FRET assays. J Neurosci Methods. 2009;183(2):238–240. [PubMed]
79. Martínez-García A, Sastre I, Tenorio R, Bullido MJ. SNP genotyping with FRET probes. Optimizing the resolution of heterozygotes. Mol Cell Probes. 2004;18:211–214. [PubMed]
80. Calero O, Hortigüela R, Albo C, de Pedro-Cuesta J, Calero M. Allelic discrimination of genetic human prion diseases by real-time PCR genotyping. Prion. 2009;3(3):146–150. [PMC free article] [PubMed]
81. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ. The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes. 2009;2:105. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science